tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

JBM (Healthcare) Completes Strategic Acquisition to Expand Chinese Medicine Portfolio

Story Highlights
JBM (Healthcare) Completes Strategic Acquisition to Expand Chinese Medicine Portfolio

Elevate Your Investing Strategy:

An update from JBM (Healthcare) Ltd. ( (HK:2161) ) is now available.

JBM (Healthcare) Limited has completed the acquisition of a target company, gaining a 90% interest and making it a non-wholly owned subsidiary. This acquisition, valued at HK$171 million, is expected to enhance JBM’s portfolio by integrating the target company’s well-known product, Tin Hee Tong Tin Hee Pills, into its offerings. The move is anticipated to create synergies and expand JBM’s market reach, leveraging its experience in brand management and distribution networks.

More about JBM (Healthcare) Ltd.

JBM (Healthcare) Limited operates in the healthcare industry, focusing on proprietary Chinese medicines and health and wellness products. The company is known for its expertise in promoting branded medicines and has a strong market presence in Hong Kong and mainland China.

YTD Price Performance: -6.32%

Average Trading Volume: 856,775

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$1.5B

For an in-depth examination of 2161 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1